Abstract：
Reduced brain derived neurotrophic factor (BDNF) concentration is reported to be associated with a cognitive decline in schizophrenia, depending on the stage of the disease. Aim of the study was to examine the possible association between plasma BDNF and cognitive decline in chronic stable schizophrenia and mild cognitive impairment (MCI). The study included 123 inpatients of both sexes with schizophrenia, 123 patients with MCI and 208 healthy control subjects. Cognitive abilities were assessed using mini mental state examination (MMSE), Clock Drawing test (CDT) and cognitive subscale of the Positive and Negative Syndrome Scale (PANSS). Plasma BDNF concentration was determined using ELISA. BDNF concentration was lower in patients with schizophrenia and MCI compared to age-matched healthy controls and was similar in carriers of different BDNF Val/66Met genotypes. The MMSE and CDT scores were lower in patients with schizophrenia compared to healthy controls and subjects with MCI. Reduced plasma BDNF was significantly associated with lower MMSE scores in all subjects. BDNF concentration in patients with schizophrenia was not affected by clinical and demographic factors. BDNF Val66Met polymorphism was not associated with the MMSE scores in all participants. Further studies should include longitudinal follow-up and other cognitive scales to confirm these results and offer cognition-improving strategies to prevent cognitive decline in chronic schizophrenia.
摘要：
据报道，脑源性神经营养因子（BDNF）浓度降低与精神分裂症的认知能力下降有关，取决于疾病的阶段。该研究的目的是检查血浆BDNF与慢性稳定期精神分裂症和轻度认知障碍（MCI）的认知功能下降之间的可能关联。这项研究包括123名男女精神分裂症患者，123名MCI患者和208名健康对照受试者。使用小型精神状态检查(MMSE)评估认知能力，时钟绘制测试（CDT）和阳性和阴性综合征量表（PANSS）的认知子量表。使用ELISA测定血浆BDNF浓度。与年龄匹配的健康对照组相比，精神分裂症和MCI患者的BDNF浓度较低，并且在不同BDNFVal/66Met基因型的携带者中相似。与健康对照和MCI受试者相比，精神分裂症患者的MMSE和CDT评分较低。在所有受试者中,降低的血浆BDNF与较低的MMSE评分显著相关。精神分裂症患者的BDNF浓度不受临床和人口统计学因素的影响。BDNFVal66Met多态性与所有参与者的MMSE评分无关。进一步的研究应包括纵向随访和其他认知量表，以证实这些结果，并提供认知改善策略以防止慢性精神分裂症的认知下降。
